J&J Rybrevant/Lazcluze study shows superiority over Tagrisso
J&J added that overall survival was continuing to be assessed, with longer-term follow-up as a key secondary endpoint. It ...
Johnson & Johnson’s rybrevant plus lazcluze featured in lung cancer presentation
Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...
PMLiVE18d
J&J’s Lazcluze/Rybrevant combination granted MHRA approval for lung cancer
The drug has been authorised for use alongside J&J’s approved cancer drug Rybrevant (amivantamab) to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and ...
manilatimes1mon
CHMP recommends subcutaneous RYBREVANT® (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
"The subcutaneous formulation of amivantamab offers an improved treatment experience for patients, reducing administration time from hours to minutes and substantially lowering rates of ...